GoodRx Holdings, Inc. (GDRX)
NASDAQ: GDRX · Real-Time Price · USD
2.680
0.00 (0.00%)
At close: Jan 16, 2026, 4:00 PM EST
2.700
+0.020 (0.75%)
After-hours: Jan 16, 2026, 7:42 PM EST
GoodRx Holdings Stock Forecast
Stock Price Forecast
The 10 analysts that cover GoodRx Holdings stock have a consensus rating of "Buy" and an average price target of $4.80, which forecasts a 79.10% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $7.00.
Price Target: $4.80 (+79.10%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for GoodRx Holdings stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 3 | 2 |
| Hold | 4 | 4 | 4 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $5 → $4.5 | Strong Buy | Maintains | $5 → $4.5 | +67.91% | Jan 9, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $5 → $4 | Hold | Maintains | $5 → $4 | +49.25% | Dec 18, 2025 |
| Barclays | Barclays | Sell Initiates $3 | Sell | Initiates | $3 | +11.94% | Dec 9, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $6 → $5 | Buy | Maintains | $6 → $5 | +86.57% | Nov 11, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +123.88% | Nov 10, 2025 |
Financial Forecast
Revenue This Year
810.56M
from 792.32M
Increased by 2.30%
Revenue Next Year
831.85M
from 810.56M
Increased by 2.63%
EPS This Year
0.37
from 0.04
Increased by 819.48%
EPS Next Year
0.45
from 0.37
Increased by 21.01%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 836.5M | 892.3M | ||||
| Avg | 810.6M | 831.9M | ||||
| Low | 777.1M | 773.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 5.6% | 10.1% | ||||
| Avg | 2.3% | 2.6% | ||||
| Low | -1.9% | -4.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.40 | 0.53 | |||
| Avg | 0.37 | 0.45 | |||
| Low | 0.33 | 0.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 897.5% | 42.7% | |||
| Avg | 819.5% | 21.0% | |||
| Low | 733.0% | 3.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.